Alkermes (ALKS) appears to be a highly specialized Biotech working on rare conditions to help with managing the effect of the condition. Recently Alkermes (ALKS) took a tumble and the stock dropped from $75 to $55. Can it recover?
First of all, the SCTR has popped back up. The relative strength line shown in white is still climbing. The price clearly broke out of the downtrend and looks to have more upside. The MACD on this stock rarely goes below zero.